The NPM1, FLT3, and CEBPA test is a specialized diagnostic assessment conducted to identify genetic mutations within the NPM1, FLT3, and CEBPA genes. These genes are critically involved in the regulation of cell growth and apoptosis, and mutations in these genes are often associated with acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. The test plays a crucial role in the diagnosis and management of AML, as the presence of mutations in these genes can influence prognosis and guide treatment decisions, including the use of targeted therapies.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a sample of blood or bone marrow from the patient. The sample is then analyzed using advanced molecular techniques to detect the presence of mutations in the NPM1, FLT3, and CEBPA genes. The results of this test can provide valuable information for the clinical management of individuals with AML, including risk stratification and the selection of appropriate therapeutic strategies.
The cost of the NPM1, FLT3, and CEBPA test at DNA Labs UAE is 3900 AED. This price reflects the comprehensive nature of the test, encompassing the detailed analysis required to identify specific genetic mutations. Given the importance of these mutations in the prognosis and treatment of AML, the test represents a critical step in the personalized care of patients with this condition.
The "Targeted Mutation Analysis More Than 2 Mutations Test" offered by DNA Labs UAE is a specialized genetic test designed to identify the presence of specific mutations across various genes. This test is particularly useful for individuals with a family history of genetic disorders, or for those who are at risk of hereditary diseases. By analyzing more than two genetic mutations, the test provides a comprehensive overview of the individual's genetic predisposition to certain conditions, enabling precise and personalized medical interventions.
The process involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory using advanced genetic sequencing technologies. This allows for the accurate detection of specific mutations that could be linked to a wide range of genetic disorders.
Priced at 3900 AED, the test is a valuable tool for early detection and preventive healthcare planning. It offers insights that can guide healthcare providers in developing targeted treatment plans, lifestyle adjustments, or preventive measures to mitigate the risk of developing genetic conditions. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and expertise in genetic testing, patients can expect reliable and comprehensive results that can significantly impact their health management strategies.
Alper's Syndrome, also known as Progressive Neuronal Degeneration of Childhood, is a rare, autosomal recessive disorder that affects the brain, liver, and muscles, leading to severe neurological and hepatic dysfunction. It is primarily caused by mutations in the POLG gene, which is crucial for the replication and repair of mitochondrial DNA. Given the genetic basis of Alper's Syndrome, identifying mutations in the POLG gene can be instrumental in diagnosing the condition.
At DNA Labs UAE, individuals can undergo a genetic test specifically designed to detect mutations in the POLG gene associated with Alper's Syndrome. This test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the lab using advanced genetic sequencing techniques. The objective is to identify any pathogenic mutations in the POLG gene that may indicate a risk or presence of Alper's Syndrome.
The cost of the POLG Gene Alper's Syndrome Genetic Test at DNA Labs UAE is 4400 AED. This price includes the collection of the sample, the genetic analysis, and a comprehensive report that interprets the results. It's important for individuals considering this test to consult with a genetic counselor or a healthcare provider both before and after testing to fully understand the implications of the results and to receive guidance on possible next steps, including management and treatment options if a mutation is detected.
The HLA Pre-Transplant Workup Sensitized Recipient Panel 5 Test is a specialized diagnostic assessment designed for individuals awaiting organ transplantation. This test is crucial in evaluating the recipient's sensitivity to potential donors, focusing on the human leukocyte antigen (HLA) system. HLA matching is vital for transplant success, as mismatches can lead to organ rejection. The panel identifies specific antibodies that the recipient may have developed against HLA antigens, which can occur due to previous transplants, blood transfusions, or pregnancies. Understanding these sensitivities allows for a more targeted donor selection process, aiming to improve transplant outcomes and longevity.
The test is offered at DNA Labs UAE, a leading facility in genetic and molecular diagnostics. The cost of the test is set at 4000 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed. By choosing DNA Labs UAE for the HLA Pre-Transplant Workup Sensitized Recipient Panel 5 Test, patients and healthcare providers can expect accurate, reliable results that are crucial for the success of the transplantation process.
The Thrombophilia Total Profile Test is a comprehensive diagnostic examination designed to identify various genetic and acquired conditions that increase an individual's risk of forming blood clots, a condition known as thrombophilia. This test is particularly crucial for individuals who have a personal or family history of blood clots, recurrent pregnancy loss, or unexplained late-term miscarriages, as it can help guide treatment and preventive measures.
Performed at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic testing, the Thrombophilia Total Profile Test encompasses a range of assays to evaluate factors that might contribute to an increased clotting tendency. These include tests for genetic mutations such as Factor V Leiden and Prothrombin G20210A, as well as assessments of protein levels that play critical roles in the clotting process, like Protein C, Protein S, and Antithrombin.
The cost of the Thrombophilia Total Profile Test at DNA Labs UAE is 5030 AED. This investment in one's health provides valuable insights that can lead to personalized treatment plans, including recommendations for medication, lifestyle adjustments, or further monitoring, thereby significantly reducing the risk of potentially life-threatening clotting events.
Human Immunodeficiency Virus 1 (HIV-1) Genotyping and Drug Resistance Test is a crucial diagnostic procedure performed to identify the genetic makeup of the HIV-1 virus in an individual's body. This test is particularly important for tailoring antiretroviral therapy (ART) to the patient, as it helps in detecting mutations in the virus's genome that may confer resistance to specific HIV medications. By understanding the genetic variation of the virus, healthcare providers can make informed decisions on the most effective treatment plans to manage the infection and reduce the risk of treatment failure.
The test is conducted at DNA Labs UAE, a reputable facility known for its advanced diagnostic technologies and commitment to providing accurate and timely health information. The cost of the HIV-1 Genotyping and Drug Resistance Test at DNA Labs UAE is 5030 AED. This investment in health care is vital for individuals living with HIV, as it enables personalized treatment strategies that can significantly improve their quality of life and long-term health outcomes.
The SARS-CoV-2 Respiratory Comprehensive Panel Test, available at DNA Labs UAE for a cost of 4910 AED, is a sophisticated diagnostic tool designed to detect the presence of the SARS-CoV-2 virus, which is responsible for COVID-19, along with a wide range of other respiratory pathogens. This comprehensive panel test is particularly useful in scenarios where patients exhibit symptoms that could be attributed to various viral or bacterial infections, making it crucial for differential diagnosis.
By employing advanced molecular techniques, the test can simultaneously screen for multiple pathogens, ensuring a thorough assessment of the patient's respiratory health. This is especially important during flu seasons or in the context of emerging infectious diseases, where symptoms overlap and accurate diagnosis can significantly impact treatment decisions and patient outcomes.
Conducted in the state-of-the-art facilities of DNA Labs UAE, this test offers a reliable, efficient, and comprehensive approach to respiratory pathogen detection, making it a valuable tool for clinicians in managing and controlling the spread of infections, including COVID-19. The cost of 4910 AED reflects the extensive range of pathogens screened by this panel and the sophisticated technology employed in the testing process.
The "Meningoencephalitis Advantage Test" is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to swiftly and accurately detect the presence of pathogens responsible for causing meningoencephalitis. Meningoencephalitis, a severe infection that inflames both the brain (encephalitis) and the protective membranes covering the brain and spinal cord (meningitis), can be caused by a variety of bacterial, viral, and other microbial agents. Early detection and identification of the specific causative agent are crucial for the effective management and treatment of this life-threatening condition.
This test utilizes advanced molecular techniques to analyze cerebrospinal fluid or other relevant biological samples, aiming to identify the genetic material of a wide range of pathogens known to cause meningoencephalitis. Its comprehensive nature ensures a high degree of accuracy, making it an invaluable tool in the diagnostic process.
Offered at a cost of 4910 AED, the test is available at DNA Labs UAE, a leading diagnostic center known for its state-of-the-art facilities and commitment to providing high-quality healthcare services. The center employs a team of highly skilled professionals who ensure that the test is conducted efficiently and results are delivered promptly, aiding in the swift initiation of appropriate treatment protocols for affected individuals.
The "Pneumonia Plus Advantage Test" is a comprehensive diagnostic tool available at DNA Labs UAE, designed to accurately identify and differentiate the pathogens responsible for pneumonia. With a cost of 4870 AED, this advanced test targets a wide range of bacteria, viruses, and fungi that can cause pneumonia, providing clinicians with crucial information to guide effective treatment strategies. Utilizing state-of-the-art molecular techniques, the test ensures high sensitivity and specificity, making it a valuable asset in the timely and accurate diagnosis of pneumonia cases. Conducted in the sophisticated facilities of DNA Labs UAE, the Pneumonia Plus Advantage Test is an essential tool for healthcare providers aiming to improve patient outcomes through precise diagnosis and targeted therapy.
The Eosinophilic Leukemia Panel FISH (Fluorescence In Situ Hybridization) is a specialized diagnostic test designed to identify genetic abnormalities associated with eosinophilic leukemia, a rare form of leukemia characterized by the overproduction of eosinophils, a type of white blood cell. This panel specifically targets the PDGFRA, PDGFRB, and FGFR1 genes, along with the BCR-ABL fusion gene (BFB), which are known to play significant roles in the development of this disease.
The test is conducted by examining the patient's DNA samples under a fluorescence microscope to detect any chromosomal abnormalities or gene fusions that may be present. This method allows for a high level of precision in identifying specific genetic mutations and chromosomal rearrangements that are critical in the diagnosis and management of eosinophilic leukemia.
Offered at DNA Labs UAE, the cost of the Eosinophilic Leukemia Panel FISH test is 4870 AED. The results from this test can provide essential information for the accurate diagnosis of eosinophilic leukemia, which is crucial for determining the most effective treatment plan for the patient. By identifying the specific genetic abnormalities involved, healthcare providers can tailor therapies that target these mutations, potentially leading to better outcomes for those affected by this rare form of leukemia.
